Here's Our 7 Picks From JD's Annual Summer Sale
Stocking a range of pieces for all occasions, it's now dropping prices by up to 50% off retail on over 1,000 footwear styles across its site. From New Balance to Nike, expect to find an array of brands, silhouettes, and colorways at a discount price to add to your summer rotation.
We've rounded up our seven picks from the JD summer sale to provide a snapshot of what to expect.
Having seen the relaunch of its archival low-profile silhouettes dominating sneaker trends over the past year, thePUMASpeedcathas become one of the brand's best-selling models. This iteration sees the premium cow leather upper get a 'Haute Coffee' and 'Frosted Ivory' makeover while the race-shoe-inspired outsole's IMEVA cushioning offers a lightweight feel. Coming in at £50 GBP (approx. $69 USD), it now arrives at over 40% below retail.
The newest addition to the iconic Air Max innovation series,Nikedebuted theAir Max Dnlast year to sneaker acclaim. Boasting a new-and-improved dynamic air unit system as well as dual-pressure tubes to shift the air underfoot, the design is crafted with comfort in mind. Arriving in 'Pure Platinum' and 'White' with tonal Swoosh and 'University Red' Air Max branding — this colorway is the perfect addition to your summer rotation. With 35% off, these sneakers come in at £100 GBP (approx. $138 USD).
Revered for its range of outdoor, functional sneaker models, theMerrellSpeed Arc Matisis the latest iteration of its trail series. As well as a mesh upper for added breathability, an innovative dual layered FloatPro Foam midsole offers enhanced cushioning that sits on top of a Vibram MegaGrip sole to tackle any terrain. Arriving in a neutral 'Green,' 'Black' and 'Brown' colorway, it's available on JD at 50% off for £80 GBP (approx. $100 USD).
A prime contender to the penny loafer,Timberland's classic 3-Eye Boat Shoes have long been a summer go-to for those looking for a change from everyday sneakers. With a versatile utilitarian look, color-block leather panels and durable leather stitching, the brand's signature lugged tread offers both comfort and style. Down over half of retail to £80 GBP (approx. $100 USD), you've got to be quick to grab yourself a pair at this price.
You can never have too many white kicks in your rotation, and theseASICSGEL-KINETIC FLUENTare no different. Known for its versatility and comfort through its signature GEL midsole, this silhouette arrives in a 'White' and 'Silver' colorway and cut from light and breathable mesh with durable synthetic overlays. Priced at 30% under retail, this sneaker is now £120 GBP (approx. $165 USD).
While running sneakers defineHOKA's legacy, it's the innovative tech behind its designs that are built for all-day comfort. Here, the Speedgoat 6 silhouette gets aGORE-TEXwaterproof membrane makeover for long-lasting wear as well as a hardwearingVibramMegagrip with Traction Lug outsole for extra grip on the trails and an extended protective toe rand. Coming in a stealthy, camo-like 'Black' and 'Outer Orbit' colorway, the sneaker features tonal branding on the lateral sides. At £110 GBP (approx. $150 USD), this drop is 30% off retail on JD this summer.
Over the years, JD has hosted a selection of collabs under its name, and with this retailer-exclusiveNew Balance1906R, it sees the silhouette revamped in a gradient colorway that boasts a layered upper and a TPU heel cage above its signature N-ergy midsole and ABZORB SBS heel cushion. Providing everything the brand has to offer in the footwear realm — comfort, versatility and bold aesthetics — JD is now offering this silhouette for 30% off at £100 GBP (approx. $138 USD).
JD's summer sale is running until July, whilst stock lasts. Be sure to check out the full range of deals on itswebsitenow.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Nothing releases its first over-the-ear headphones, the $299 Headphone (1)
London-based smartphone maker Nothing has launched its first over-the-ear headphones, the Headphone (1). The new device follows Nothing's first step into audio hardware with last year's debut of the Ear 2 open-ear headphones. The new Headphone (1) headphones were designed in collaboration with British audio brand KEF and feature the sleek, transparent design that Nothing has become known for. The device itself is a bit bulky, even for an over-the-ear headphone, but it provides adequate adaptive noise cancelling and transparent modes. This model also offers adaptive bass enhancement, which came across when listening to a variety of music genres. In addition, the headphones offer immersive spatial audio. This creates a 3-D listening experience that, paired with the dynamic head tracking, creates a more lifelike audio experience. A highlight is the tactile buttons. Nothing stepped away from sensors in favor of a simple button to trigger your AI assistant or ChatGPT, if you have the Nothing X app, and a volume roller that can also be pressed to play, pause, and turn on and off noise canceling. Plus, the roller has a very satisfying click when you turn it up or down. The headphones were a bit heavy and tended to slide around while wearing them to do some household chores, but were otherwise perfectly comfortable for a long wear time. The company claims a long battery life with up to 80 hours of listening, 35 hours if you have noise cancelling turned on, and a quick charge time. The Headphone (1) will be available for preorder in the U.S., U.K., and elsewhere starting on July 4, 2025, for $299. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
NEAR Protocol Falls 2% as Support Level Faces Critical Test
AI-focused NEAR token is down by 2% on Tuesday to reflect broader altcoin market weakness and a negative response to a governance proposal by trading firm DWF Labs. DWF proposed to cut NEAR's inflation from 5% to 2.5%. While this might have a bullish impact on prices in that tokens will be more scarce, network validators might switch to other networks if their rewards are slashed too much, creating a debate over a potential lack of decentralization. Technical analysis The 19:00-20:00 period on June 30th marked the peak with the highest price point, followed by consistent lower highs, suggesting continued selling pressure that could test the established support zone in the near term. In the last 60 minutes from 1 July 13:06 to 14:05, NEAR-USD demonstrated a strong bullish trend, rising from $2.08 to $2.10, representing a 1% gain. The price action formed a clear upward channel with higher lows and higher highs, particularly accelerating between 13:25-13:33 when price broke above the $2.08 resistance and quickly established support at $2.09. A notable volume spike occurred at 13:40-13:41, creating a brief pullback to $2.08 before buyers stepped in, pushing price to the session high of $2.10 by 14:05. This recovery from the mid-session dip confirms strong underlying demand and suggests potential continuation of the uptrend. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
AstraZeneca stock rises amid reports CEO favors US listing move
-- AstraZeneca PLC (NASDAQ:AZN) ADRs rose 2.2% following a Times report that CEO Sir Pascal Soriot has privately expressed interest in moving the company's stock market listing to the United States. According to The Times, citing sources familiar with his thinking, Soriot has discussed his preference for relocating the FTSE 100 company's listing on multiple occasions and has even considered moving AstraZeneca's domicile. However, such a move would likely face resistance from parts of the board and the British government, which reportedly has not been informed of these discussions. Soriot, who has led the pharmaceutical giant since 2012, has publicly voiced concerns about Europe falling behind the US and China in developing innovative medicines. These two markets represent AstraZeneca's largest revenue sources globally. The CEO is reportedly "deeply frustrated" with the UK's operating environment, particularly regarding restrictions on new medicine approvals by the National Institute for Health and Care Excellence (Nice). Specific concerns include approval challenges for drugs and pricing constraints under the NHS sales rebate scheme. As Britain's most valuable public company, any potential move by AstraZeneca would represent a significant shift in the UK corporate landscape. The company has become a cornerstone of the British pharmaceutical industry under Soriot's leadership over the past decade. Related articles AstraZeneca stock rises amid reports CEO favors US listing move INmune slides again as Scotiabank, RJ cut ratings after Alzheimer's drug miss Wolfe Research refreshes high-conviction ideas heading into H2 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
